Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.93 Insider Own3.00% Shs Outstand144.44M Perf Week4.91%
Market Cap2.56B Forward P/E- EPS next Y-0.79 Insider Trans0.00% Shs Float122.96M Perf Month6.10%
Income-120.00M PEG- EPS next Q0.06 Inst Own85.80% Short Float11.30% Perf Quarter35.42%
Sales134.20M P/S19.09 EPS this Y-216.50% Inst Trans-1.36% Short Ratio11.11 Perf Half Y38.38%
Book/sh0.43 P/B41.26 EPS next Y-507.70% ROA-43.00% Target Price18.80 Perf Year82.70%
Cash/sh2.06 P/C8.61 EPS next 5Y55.00% ROE- 52W Range8.18 - 18.43 Perf YTD79.55%
Dividend- P/FCF- EPS past 5Y-33.10% ROI-45.80% 52W High-3.74% Beta2.09
Dividend %- Quick Ratio3.90 Sales past 5Y21.20% Gross Margin75.80% 52W Low116.87% ATR0.64
Employees259 Current Ratio4.10 Sales Q/Q1.50% Oper. Margin-73.20% RSI (14)68.64 Volatility3.65% 3.33%
OptionableYes Debt/Eq3.63 EPS Q/Q-9.30% Profit Margin-89.40% Rel Volume0.61 Prev Close17.86
ShortableYes LT Debt/Eq2.84 EarningsNov 07 AMC Payout- Avg Volume1.25M Price17.74
Recom2.30 SMA203.44% SMA5021.36% SMA20032.42% Volume758,399 Change-0.67%
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jan-10-14Reiterated Barclays Equal Weight $12 → $15
Nov-11-13Reiterated UBS Neutral $8 → $14
Nov-11-13Reiterated Barclays Equal Weight $8 → $12
Aug-02-13Downgrade Barclays Overweight → Equal Weight $9 → $8
May-01-13Reiterated UBS Neutral $8 → $6.50
Sep-24-12Reiterated Barclays Overweight $8 → $10
Oct-18-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $9
Apr-01-11Initiated Stifel Nicolaus Buy $10
Oct-17-17 07:32AM  3 Drug Stocks Hitting 52-Week Highs: Are They Buys? Motley Fool
Oct-16-17 09:46AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
08:00AM  Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients PR Newswire
Oct-13-17 08:00AM  Todays Research Reports on Trending Tickers: Halozyme Therapeutics and Akers Biosciences ACCESSWIRE
Oct-10-17 08:00AM  Halozyme to Host Third Quarter 2017 Financial Results Conference Call PR Newswire
06:03AM  3 Monster Stocks in the Making Motley Fool
Oct-06-17 10:53AM  ETFs with exposure to Halozyme Therapeutics, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:34AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Oct-02-17 08:05AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Sep-29-17 11:34AM  1 Great Biotech Stock You Have Never Heard Of Motley Fool
Sep-28-17 08:05AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Sep-22-17 08:35AM  Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions? Zacks
Sep-20-17 08:45AM  Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook Zacks
Sep-16-17 10:47AM  Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? Motley Fool
Sep-15-17 11:33PM  [$$] Charting the Market Barrons.com
09:34AM  Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE Zacks
08:31AM  Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2% Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Halozyme Therapeutics and Array Biopharma ACCESSWIRE
03:00AM  Stocks To Watch: Halozyme Therapeutics Sees Relative Strength Rating Rise To 90 Investor's Business Daily
Sep-14-17 04:30PM  Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today Motley Fool +21.24%
04:20PM  This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche Investor's Business Daily
03:43PM  Halozyme to license drug delivery tech to Bristol-Myers a... CNBC Videos
11:45AM  Here's Why Halozyme Therapeutics, Inc. Is Soaring Today Motley Fool
08:45AM  Halozyme Therapeutics Wins Big on Roche License Agreement 24/7 Wall St.
08:00AM  Halozyme to license drug delivery tech to Roche, Bristol-Myers Reuters
08:00AM  Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take Forbes
07:18AM  Halozyme's stock soars after Bristol-Myers license deal MarketWatch
07:05AM  Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties PR Newswire
07:05AM  Halozyme Increases 2017 Financial Guidance PR Newswire
07:00AM  Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers TheStreet.com
06:59AM  Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology Business Wire
Sep-11-17 08:06AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Sep-01-17 09:59AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : September 1, 2017 Capital Cube
Aug-30-17 03:00AM  Stocks Generating Improved Relative Strength: Halozyme Therapeutics Investor's Business Daily
Aug-25-17 08:00AM  Halozyme Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Aug-23-17 08:05AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Aug-16-17 08:06AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Aug-13-17 09:35AM  Edited Transcript of HALO earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
09:05AM  Edited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:05AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Aug-11-17 08:06AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Aug-08-17 11:40PM  Halozyme Therapeutics reports 2Q loss Associated Press
04:05PM  Halozyme Reports Second Quarter 2017 Results PR Newswire
10:20AM  Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:26AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : August 8, 2017 Capital Cube
Aug-04-17 04:15PM  Halozyme Therapeutics To Present At Upcoming Healthcare Conference PR Newswire
Aug-03-17 10:37PM  Halozyme Therapeutics, Inc. Value Analysis (NASDAQ:HALO) : August 4, 2017 Capital Cube
Jul-21-17 08:39AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : July 21, 2017 Capital Cube
Jul-13-17 08:30AM  Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy PR Newswire
Jul-10-17 04:39PM  Investor thought Martin Shkreli was like 'Rain Man' character because of his financial focus CNBC
04:15PM  Halozyme To Host Second Quarter 2017 Financial Results Conference Call PR Newswire
Jul-07-17 04:28PM  Former officer of Martin Shkreli hedge fund filed SEC complaint against Shkreli while at fund CNBC
01:32PM  Martin Shkreli worker called him 'mentally unstable,' threatened to expose lies by 'scam artist' CNBC
Jul-06-17 07:02PM  Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded' CNBC
04:58PM  Shkreli kept hedge-fund investor in dark about botched trade, misled him about auditors: testimony CNBC
12:38PM  Martin Shkreli's lawyer and 'cowboy' venture capitalist duel over value of horses and investments CNBC
Jun-30-17 09:27AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June 30, 2017 Capital Cube
Jun-28-17 12:00PM  Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium PR Newswire
Jun-26-17 04:06PM  ETFs with exposure to Halozyme Therapeutics, Inc. : June 26, 2017 Capital Cube
08:00AM  Halozyme FDA Action Date, Q1 Review, Analysts Outlook and Price Targets Accesswire
Jun-22-17 03:16PM  FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology PR Newswire
Jun-19-17 08:22AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : June 19, 2017 Capital Cube +5.43%
Jun-16-17 03:51PM  ETFs with exposure to Halozyme Therapeutics, Inc. : June 16, 2017 Capital Cube
Jun-15-17 04:05PM  Benzinga's Option Alert Recap From June 15 Benzinga
Jun-14-17 09:15AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-06-17 09:14AM  Why Halozyme Therapeutics Inc. Sank 16.5% in May Motley Fool
Jun-04-17 11:45AM  Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO PR Newswire
May-25-17 04:05PM  Halozyme Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
May-24-17 04:05PM  Halozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
May-22-17 08:38AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May 22, 2017 Capital Cube
May-19-17 04:55PM  Why Halozyme Therapeutics, Seadrill, and Sibanye Gold Slumped Today Motley Fool -8.83%
04:27PM  Halozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10% Motley Fool
09:16AM  Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme TheStreet.com
May-18-17 09:25PM  Halozyme Therapeutics Prices Public Offering Of Common Stock PR Newswire
04:49PM  Halozyme shares fall after secondary share offering annoucned MarketWatch
04:05PM  Halozyme Therapeutics Announces Public Offering Of Common Stock PR Newswire
08:15AM  Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results Accesswire
May-17-17 05:29PM  Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO PR Newswire -5.62%
May-10-17 09:31PM  Edited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-09-17 06:10PM  Halozyme Therapeutics reports 1Q loss Associated Press
04:05PM  Halozyme Reports First Quarter 2017 Financial Results PR Newswire
10:15AM  Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call Accesswire
Apr-24-17 03:24PM  Halozyme Therapeutics, Inc. Value Analysis (NASDAQ:HALO) : April 24, 2017 Capital Cube
Apr-21-17 08:47AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : April 21, 2017 Capital Cube
Apr-20-17 06:22PM  If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.com
Apr-10-17 04:15PM  Halozyme To Host First Quarter 2017 Financial Results Conference Call PR Newswire
Apr-06-17 08:29AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : April 6, 2017 Capital Cube
Apr-03-17 08:00AM  Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models PR Newswire
Mar-31-17 09:30AM  Rosetta Genomics and Halozyme Therapeutics: Wait for Better News Accesswire
Mar-30-17 11:48AM  Here's Why Halozyme Therapeutics, Inc Is Falling Motley Fool -8.82%
09:54AM  Biotech Premarket Movers: Halozyme, Omeros, Aralez TheStreet.com
08:30AM  Halozyme Provides Update On SWOG Collaborative Group Clinical Study PR Newswire
Mar-29-17 08:32PM  ETFs with exposure to Halozyme Therapeutics, Inc. : March 30, 2017 Capital Cube
12:44PM  FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology PR Newswire
Mar-06-17 01:44PM  ETFs with exposure to Halozyme Therapeutics, Inc. : March 6, 2017
Mar-04-17 01:04PM  HALOZYME THERAPEUTICS INC Financials
Mar-02-17 10:38AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Capital Cube
09:22AM  5 Small-Cap Biotech Stocks to Buy in March Motley Fool
Mar-01-17 04:03AM  Edited Transcript of HALO earnings conference call or presentation 28-Feb-17 9:30pm GMT
Feb-28-17 07:03PM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stelzer LaurieSVP, Chief Financial OfficerJun 15Option Exercise0.006,875027,785Jun 16 04:10 PM
KIRK RANDAL JDirectorMay 11Option Exercise10.3710,000103,7003,562,388May 15 09:09 AM
MATSUI CONNIEDirectorMay 08Option Exercise10.3710,000103,700247,388May 09 06:00 PM
LEONHARDT HARRY JSVP, GC and CCOApr 13Option Exercise0.006,875020,382Apr 14 02:03 PM
Torley HelenPresident and CEOFeb 06Option Exercise0.0031,2500244,159Feb 07 04:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,120029,995Feb 06 07:01 PM
Countouriotis AthenaSVP and Chief Medical OfficerFeb 03Option Exercise0.0018,496045,977Feb 06 07:01 PM
LEONHARDT HARRY JSVP, GC and CCOFeb 03Option Exercise0.0015,413019,705Feb 06 07:01 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870212,909Feb 06 07:00 PM
Torley HelenPresident and CEOJan 06Option Exercise0.0030,0000157,422Jan 09 04:04 PM
Countouriotis AthenaSVP and Chief Medical OfficerJan 05Option Exercise0.007,500027,481Jan 09 04:03 PM
open in yahoo | open in reuters | open in google